Reading this on a mobile device? Try our optimized mobile version here: http://r.smartbrief.com/resp/dplECrsecrpQrWldoYzt

December 14, 2011
Sign upForwardArchiveAdvertise
How I See It
Q&A with Dr. Ron Cohen
of Acorda Therapeutics
  
Acorda Therapeutics CEO and BIO board member Dr. Ron Cohen talks about how the regulatory process can be improved to get promising drugs to patients, the continued expectation of a large wave of pharmaceutical mergers and acquisitions as well as partnerships, and the prospect for biotech innovation in 2012. A funding crisis at the FDA is making it harder for regulatory processes to keep up with advances in science, he says, and a national strategy is needed that recognizes innovation, speeds the review of applications and promotes science-based decision making. SmartBrief/SmartBlog on Leadership (12/13)
LinkedInFacebookTwitterEmail this Story

How You See It
Poll: The most important factor in my company and industry's success next year will be:
26%   The economy and demand for products and services
24%   The availability of funding and investment
22%   Research and innovation
16%   The regulatory process
12%   Partnership decisions
  LinkedInFacebookTwitterEmail this Story
Poll: What do you think 2012 holds for venture capital, grants and other investments in the life sciences?
44%   Increased merger-and-acquisition activity
27%   Emphasis on late-stage commercialization
15%   Emphasis on early-stage discovery
14%   A window for IPOs
  LinkedInFacebookTwitterEmail this Story
Poll: The commissioner of the FDA has said the agency must advance regulatory science and be a catalyst for innovation. In 2012, what do you expect?
33%   Improvement will come, but it will take longer than a year
30%   The changes will be incremental and ineffective
16%   Investment and innovation will be greater in unregulated fields of the life sciences
14%   The push to streamline regulation will instead make the process more difficult
6%   The push to streamline regulation will bring faster approvals and clearances
  LinkedInFacebookTwitterEmail this Story
Poll: What field is most likely to yield the biggest breakthrough in the coming year?
23%   Stem-cell therapies
14%   Specific disease therapies -- HIV, cancer
14%   Vaccines
12%   Someplace unexpected
10%   Genomic discoveries
8%   Advanced biofuels
8%   Agricultural biotech
7%   Gene therapy
4%   Synthetic biology
  LinkedInFacebookTwitterEmail this Story

BIO Resources
Unleashing the Promise of Biotechnology
Biotechnology provides breakthrough products to cure disease, protect against bioterrorism, feed the hungry and clean our environment, and society has tapped just a small fraction of its potential benefits. Biotech research and development is a high-risk undertaking because of substantial startup costs, lengthy experimentation and the possibility that the technology will not prove viable. Complicating matters, regulatory review processes are not keeping up with rapidly advancing science. Learn more about a policy agenda that we believe will enable U.S. biotech companies to transform the innovative ideas of today into the realities of tomorrow.
LinkedInFacebookTwitterEmail this Story
  • World Congress on Industrial Biotech
    The world's largest industrial biotech event featuring business leaders, investors and policymakers in biofuels, biobased products and renewable chemicals. April 31 to May 2 in Orlando, Fla. Learn more.
    LinkedInFacebookTwitterEmail this Story
 

Product announcements appearing in SmartBrief are paid advertisements and do not reflect actual BIO endorsements. The news reported in SmartBrief does not necessarily reflect the official position of BIO.

Most Popular Stories

These are the most clicked and shared stories in BIO SmartBrief in the past year.

FDA uncovers falsified research data from contractor Cetero
Reuters (7/26)
Research examines drugs' odds of getting FDA approval
Reuters (2/14)
Boston takes top spot in ranking of life sciences clusters
Mass High Tech (Boston) (11/29)
Merck to invest in biotech startups with $250 million venture fund
In Vivo Blog (9/15), Xconomy (9/15)
Expert shares 2011 forecast for the biotech industry
MedCityNews.com (12/31)
Sanofi CEO explains R&D strategy and investment plan
American City Business Journals/Boston (4/14)
Expert identifies biotechs that are likely to draw buyout bids
CNBC (4/18)
Sandoz is working on 10 follow-on biologics, exec says
Reuters (2/9)
Venter says biotech algae may lead to unlimited supply of energy
The Washington Post (8/11)
Samsung will join biopharma market through venture with Quintiles
Reuters (2/24)
LinkedInFacebookTwitterEmail this Story

Smartest Quotes

These are the most clicked and shared SmartQuotes in BIO SmartBrief in the past year.

Some men have thousands of reasons why they cannot do what they want to, when all they need is one reason why they can.
-- Willis R. Whitney,
American chemist
Too many people overvalue what they are not and undervalue what they are.
-- Malcolm Forbes,
American magazine publisher
Whatever you can do, or dream you can, begin it. Boldness has genius, power and magic in it.
-- Johann Wolfgang von Goethe,
German writer and scientist

LinkedInFacebookTwitterEmail this Story
Only in North Carolina can you find so many unique innovations to help heal, fuel AND feed the world. Discover NC’s complete package and why 538 companies call NC home.
 
Subscriber Tools
     
Print friendly format | Web version | Search past news | Archive | Privacy policy

Advertise
Account Director:  Meryl Harold (202) 407-7828
 
Read more at SmartBrief.com
A powerful website for SmartBrief readers including:
 
 
 Recent BIO SmartBrief Issues:   Lead Editor:  Tom Parks
     
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
 
 
© 1999-2011 SmartBrief, Inc.® Legal Information